{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T22:30:20Z","timestamp":1790980220630,"version":"4.1.0"},"reference-count":22,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2010,8,5]],"date-time":"2010-08-05T00:00:00Z","timestamp":1280966400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2010,10]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Mantle cell lymphoma (MCL) outcomes have improved over the last two decades; however, late relapses occur. Bortezomib has shown single agent activity of 33% in relapsed MCL and has an additive\/synergistic effect <jats:italic>in vitro<\/jats:italic> when combined with drugs currently used to treat MCL. We hypothesized that a combination of bortezomib with current intense non\u2010transplant chemoimmunotherapy might prevent late relapses. The toxicity of bortezomib when combined with methotrexate and cytarabine is unknown. Patients aged 18\u201379\u2003years with untreated aggressive MCL were treated with R\u2010HyperCVAD (rituximab, cyclophosphamide, vincristine, doxorubicin, dexamethasone) alternating with rituximab\u2010methotrexate\/cytarabine (R\u2010M\/A). Bortezomib was added to the R\u2010Hyper\u2010CVAD combination as a fixed dose of 1\u00b73\u2003mg\/m<jats:sup>2<\/jats:sup> IV on days 2 and 5 and was added to the R\u2010M\/A regimen after rituximab, in increasing doses of 0\u00b77, 1, and 1\u00b73\u2003mg\/m<jats:sup>2<\/jats:sup> in cohorts of three patients. Twenty patients were assessed for toxicity of the regimen. The principal toxicity was haematological and did not differ from that observed with a similar regimen without the bortezomib. In particular, there was no pulmonary or neurological dose\u2010limiting toxicity, showing that bortezomib can be safely combined with R\u2010HyperCVAD and R\u2010M\/A.<\/jats:p>","DOI":"10.1111\/j.1365-2141.2010.08315.x","type":"journal-article","created":{"date-parts":[[2010,8,6]],"date-time":"2010-08-06T14:41:58Z","timestamp":1281105718000},"page":"47-53","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["Phase I trial of bortezomib in combination with rituximab\u2010HyperCVAD alternating with rituximab, methotrexate and cytarabine for untreated aggressive mantle cell lymphoma"],"prefix":"10.1111","volume":"151","author":[{"given":"Jorge E.","family":"Romaguera","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis E.","family":"Fayad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"McLaughlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Pro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alma","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"Weaver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly","family":"Hartig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larry W.","family":"Kwak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatyana","family":"Feldman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judy","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peggy","family":"Ford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart","family":"Goldberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Pecora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andre","family":"Goy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,8,5]]},"reference":[{"key":"e_1_2_6_2_1","first-page":"4464","article-title":"In vitro studies of bortezomib with daunorubicin and cytarabine: sequence of administration affects leukemia cell chemosensitivity","volume":"104","author":"Attar E.C.","year":"2004","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1993.11.3.570"},{"key":"e_1_2_6_4_1","first-page":"3395","article-title":"Sensitization of leukemic cells for glucocorticoids by inhibition of NFKB activation","volume":"104","author":"Cloos J.","year":"2004","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.07.9665"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1532\/IJH97.06142"},{"key":"e_1_2_6_7_1","first-page":"1387","article-title":"Sensitivity, schedule\u2010dependence and molecular effects of the proteasome inhibitor bortezomib in non\u2010Hodgkin\u2019s lymphoma cells","volume":"104","author":"Goy A.","year":"2004","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.16.8435"},{"key":"e_1_2_6_9_1","volume-title":"World Health Organization Classification of Tumours: Pathology and Genetics of Turnouts of Haematopoietic and Lymphoid Tissues","author":"Jaffe E.S.","year":"2001"},{"key":"e_1_2_6_10_1","first-page":"1661","article-title":"The VcR\u2010CVAD regimen produces a high complete response rate in untreated mantle cell lymphoma (MCL): first analysis of E1405 \u2013 A phase II study of VcR\u2010CVAD with maintenance rituximab for MCL","volume":"114","author":"Kahl B.S.","year":"2009","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1309\/69EJ-RFM5-E976-BUTP"},{"key":"e_1_2_6_12_1","first-page":"491","article-title":"Phase I\/II trial of bortezomib\u2003+\u2003CHOP\u2010rituximab in diffuse large B cell (DLBCL) and mantle cell lymphoma (MCL): phase I results","volume":"106","author":"Leonard J.P.","year":"2005","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/ajcp\/112.4.524"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.19.6121"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-11-4541"},{"key":"e_1_2_6_16_1","first-page":"2484","article-title":"Combined targeting of the proteasome and Bcl\u20102 sensitizes human B\u2010cell lymphoma and multiple myeloma to cyclophosphamide in vitro and in vivo models of these diseases","volume":"104","author":"O\u2019Connor O.","year":"2004","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.mjt.0000245224.20913.0d"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1097\/00000421-198212000-00014"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.01.1825"},{"key":"e_1_2_6_20_1","first-page":"833","article-title":"Rituximab (R)\u2003+\u2003HyperCVAD alternating with R\u2010methotrexate\/cytarabine after 9\u2003Years: continued high rate of failure\u2010free survival in untreated mantle cell lymphoma (MCL)","volume":"112","author":"Romaguera J.E.","year":"2008","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2006.03.005"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404511"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428190902856790"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2141.2010.08315.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2141.2010.08315.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T02:53:00Z","timestamp":1697424780000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2141.2010.08315.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,8,5]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,10]]}},"alternative-id":["10.1111\/j.1365-2141.2010.08315.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2141.2010.08315.x","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,8,5]]},"assertion":[{"value":"2010-08-05","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}